C. Crews
Molecular Biology · 2001–2022
A researcher in the Science corpus: 12 papers; trusts 11 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 178 citations into it; #15,013 of 17,773 by trust here, #5,320 by citations
- Oncology — 39 citations into it; #1,688 of 1,698 by trust here, #752 by citations
- Epidemiology — 21 citations into it
- Cancer Research — 17 citations into it
Whom C. Crews trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts C. Crews overall
Papers from C. Crews's perspective
Ordered by how strongly the researchers C. Crews trusts endorse each paper. Same corpus, a different order for every researcher.
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells (Science)
- Catalytic in vivo protein knockdown by small-molecule PROTACs (Nature Chemical Biology)
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (Cancer Cell)
- A small molecule–kinase interaction map for clinical kinase inhibitors (Nature Biotechnology)
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs (Nature)
- A quantitative analysis of kinase inhibitor selectivity (Nature Biotechnology)
- RNAi therapeutics: a potential new class of pharmaceutical drugs (Nature Chemical Biology)
- Faculty Opinions recommendation of Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.
- Targeting MYC dependence in cancer by inhibiting BET bromodomains (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation (2001) — 2,057 citations
- Targeted protein degradation: expanding the toolbox (2019) — 767 citations
- Lessons in PROTAC design from selective degradation with a promiscuous warhead (2017) — 738 citations
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer (2016) — 713 citations
- Catalytic in vivo protein knockdown by small-molecule PROTACs (2015) — 1,106 citations
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. (2015) — 950 citations
- PROTAC targeted protein degraders: the past is prologue (2022) — 2,534 citations
- PROTACs: past, present and future. (2022) — 399 citations
- Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020) — 836 citations
- PROteolysis TArgeting Chimeras (PROTACs) - Past, Present and Future (2019) — 628 citations
- Induced protein degradation: an emerging drug discovery paradigm (2016) — 1,216 citations
- Molecular understanding and modern application of traditional medicines: triumphs and trials. (2007) — 642 citations